HC Wainwright Issues Negative Estimate for Celcuity Earnings

Celcuity Inc. (NASDAQ:CELC) – Stock analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for Celcuity in a report released on Tuesday, April 1st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($1.01) per share for the quarter, down from their prior estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity’s Q2 2025 earnings at ($1.04) EPS, Q3 2025 earnings at ($1.07) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($4.23) EPS, FY2026 earnings at ($4.22) EPS, FY2027 earnings at ($0.82) EPS, FY2028 earnings at $1.50 EPS and FY2029 earnings at $3.63 EPS.

Celcuity (NASDAQ:CELC) last released its earnings results on Monday, March 31st. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.13).

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Celcuity in a research report on Tuesday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Celcuity currently has an average rating of “Buy” and an average price target of $30.17.

Celcuity Price Performance

Shares of CELC opened at $9.36 on Thursday. The company has a market cap of $347.54 million, a P/E ratio of -3.59 and a beta of 0.44. Celcuity has a fifty-two week low of $8.50 and a fifty-two week high of $20.89. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The firm’s 50 day moving average price is $11.10 and its 200 day moving average price is $12.84.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its position in shares of Celcuity by 21.6% during the fourth quarter. Wellington Management Group LLP now owns 62,776 shares of the company’s stock worth $822,000 after acquiring an additional 11,165 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Celcuity by 19.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 26,377 shares of the company’s stock worth $345,000 after purchasing an additional 4,341 shares during the last quarter. Soleus Capital Management L.P. increased its stake in Celcuity by 106.0% in the fourth quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company’s stock valued at $33,577,000 after purchasing an additional 1,319,700 shares during the period. Shay Capital LLC purchased a new stake in shares of Celcuity in the fourth quarter valued at about $187,000. Finally, Nuveen Asset Management LLC grew its holdings in shares of Celcuity by 10.8% during the fourth quarter. Nuveen Asset Management LLC now owns 69,587 shares of the company’s stock worth $911,000 after buying an additional 6,785 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.